IN8bio: Advancing Next-Generation Gamma-Delta T Cell Therapies

Market Focus

IN8bio (NASDAQ: INAB) is a U.S.-based clinical-stage biotechnology company developing gamma-delta T cell immunotherapies designed to overcome key challenges in oncology treatment. The company’s platform harnesses the unique properties of gamma-delta T cells — immune cells that combine innate and adaptive immune functions — to target and eliminate cancer cells in both solid tumors and hematologic malignancies. Gamma-delta T cells naturally recognize stress-induced ligands on tumor cells, allowing IN8bio to develop therapies with broad applicability, inherent safety, and potentially superior persistence compared to conventional CAR-T approaches. With early clinical validation and growing investor interest, IN8bio is positioned at the forefront of the next wave of cell therapy innovation.

Platform and Strategy

IN8bio’s approach centers on building a differentiated and scalable gamma-delta T cell platform capable of producing both autologous (patient-derived) and allogeneic (donor-derived, off-the-shelf) products. Key elements of the company’s strategy include:

• Advancing lead clinical programs in glioblastoma multiforme (GBM) and acute myeloid leukemia (AML), demonstrating durable responses and strong immune persistence in early trials

• Developing off-the-shelf allogeneic candidates to broaden patient access and streamline manufacturing

• Leveraging proprietary genetic engineering and expansion technologies to enhance tumor targeting, persistence, and resistance to chemotherapy

• Establishing internal GMP manufacturing capabilities to control process development and enable cost-efficient scaling

• Building a diversified pipeline with potential applications across multiple solid and hematologic cancers

Recent Progress and Growth

IN8bio enters late 2025 with multiple catalysts and continued clinical and corporate momentum:

• Encouraging Phase 1 data from GBM and leukemia trials highlighting durable immune responses and early efficacy signals

• Pipeline expansion into additional solid tumor indications with next-generation allogeneic candidates

• Strengthened balance sheet through recent financings and disciplined capital management to support multi-program advancement

• Publication and presentation of new data at leading oncology and immunotherapy conferences, reinforcing IN8bio’s leadership in gamma-delta T cell science

• Operational readiness for upcoming IND filings and trial initiations anticipated in 2025

Partnerships and Strategic Positioning

IN8bio’s technology platform positions it as a leader in gamma-delta cell therapy, an emerging field with growing validation from both industry and academia. The company’s proprietary methods enable scalable, consistent manufacturing of cell products that can potentially overcome resistance seen with traditional alpha-beta T cell approaches.

Strategically, IN8bio is exploring collaborations with academic centers, biopharma partners, and non-dilutive funding programs to accelerate development and commercial readiness. As the cell therapy landscape matures, IN8bio’s differentiated immunobiology and manufacturing know-how provide a distinct competitive advantage in addressing high-unmet-need cancers.

Leadership and Capital Markets Strategy

IN8bio is led by Dr. William Ho, Chief Executive Officer, who brings deep experience in oncology development and capital markets, and Patrick McCall, Chief Financial Officer, who oversees financial strategy, operations, and investor relations. Together, they are driving a disciplined execution plan that balances clinical advancement with prudent capital allocation.

The company trades on the NASDAQ under the symbol INAB, offering investors exposure to a rapidly advancing immunotherapy platform at the intersection of cell therapy innovation and oncology precision medicine.

Near-Term Catalysts

• Additional clinical data readouts from ongoing GBM and AML trials

• Regulatory updates and IND filings for expanded allogeneic programs

• Preclinical results supporting pipeline expansion into new solid tumor indications

• Strategic partnerships and potential non-dilutive funding announcements

• Corporate and scientific presentations at major investor and oncology conferences

Conclusion

IN8bio represents a compelling opportunity to participate in the evolution of next-generation cell therapy. By harnessing the power of gamma-delta T cells, the company is advancing a platform with the potential to deliver durable, broad-based cancer treatments that overcome many of the limitations of existing modalities. Supported by an experienced management team, solid financial foundation, and multiple upcoming catalysts, IN8bio is well positioned to create meaningful value for both patients and shareholders in the years ahead.

Interested in Attending or Presenting?

🔹 Prospective Attendees: Click here to join our upcoming investor events and discover emerging opportunities across the resource, biotech, and technology sectors.

🔹 Companies Seeking Exposure: Click here to learn how to present at one of our curated investor showcases and connect with active family offices, funds, and high-net-worth investors.

For additional info or to schedule a call, feel free to reach out.

Jimmy Lederer

Vice President

Trinity Financing Investments Corporation

Phone: 347-514-0000

Email: jimmy@trinityfinancinginvestments.com

All content provided is for informational and educational purposes only and should not be construed as investment advice or an offer or solicitation in respect to any products or services. The content presented should not be used as the basis for any investment decision, and does not purport to provide any legal, tax or accounting advice. There are inherent risks involved with investing in Issuers, as set out in the public disclosure record of each Issuer. Issuers are not responsible for revising or updating any information that they present via TFIC events.

Investors should refer to the continuous disclosure documents filed by each Issuer under applicable securities laws, including risk factors and warnings regarding “forward looking information”. Issuers are solely responsible for compliance with applicable securities laws, and TFIC makes no representations and provides no assurances to Investors regarding the accuracy or truthfulness of information presented by Issuers via TFIC events or in their public disclosure records. 

TFIC does not recommend or endorse any Issuer that presents via TFIC events, nor does TFIC verify the accuracy of any information presented by Issuers to Investors via TFIC events or in their public disclosure records. TFIC’s sole responsibility as the operator of TFIC events is to provide a platform for Investors and Issuers to communicate directly.

ALL CONTENT PRESENTED BY ISSUER(S) IS PROVIDED BY THE ISSUER(S) "AS IS" AND “AS AVAILABLE”. TFIC DOES NOT GUARANTEE THE ACCURACY OF ITS CONTENT. BY ATTENDING, EACH INVESTOR AGREES TO ACCEPT ANY RISKS ASSOCIATED AND ACKNOWLEDGES THAT TFIC IS NOT RESPONSIBLE FOR ANY CONTENT PRESENTED BY OR RELATING TO ISSUERS ON THE PLATFORM. 

TFIC DOES NOT WARRANT THAT THE PROVISION OF INFORMATION BY ISSUERS IN THEIR PRESENTATION WILL BE ERROR-FREE, TIMELY, COMPLETE OR ACCURATE. ATTENDANCE AND RELIANCE ON INFORMATION RECIEVED THEREON IS AT INVESTOR’S SOLE RISK. TFIC WILL NOT BE IN ANY WAY BE LIABLE TO ANY INVESTOR OR ISSUER OR ANY OTHER ENTITY OR PERSON FOR ANY INACCURACIES, ERRORS, OMISSIONS, DELAYS, DAMAGES, CLAIMS, LIABILITIES OR LOSSES, REGARDLESS OF CAUSE, IN OR ARISING FROM THE USE OF THE PLATFORM.

IN NO EVENT WILL TFIC BE LIABLE FOR ANY DAMAGES, INCLUDING WITHOUT LIMITATION DIRECT OR INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, LOSSES OR EXPENSES ARISING IN CONNECTION WITH THE ATTENDANCE BY INVESTORS AND/OR ISSUERS EVEN IF TFIC IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, LOSSES OR EXPENSES. FURTHER, TFIC SHALL NOT BE LIABLE IN ANY MANNER FOR THE PRODUCT OR SERVICES OF ANYONE WHO REDISTRIBUTES THE INFORMATION PROVIDED ON THE PLATFORM, AND SUCH REDISTRIBUTION IS EXPRESSLY PROHIBITED.